European regulatory authorities have finalized their assessment of reported non-compliance with Good Manufacturing Practice (GMP) at Indian drugmaker Ranbaxy Laboratories’ (BSE: 500359) manufacturing site in Toansa, India, that had led to the suspension of the GMP certificate for the site in the European Union, regulators have concluded.
Although the assessment showed that there were a number of GMP deficiencies at the concerned site, assessment of all available information has reassured European regulators that there has been no risk to public health from these deficiencies, said Ranbaxy, currently majority-owned by Japan’s Daiichi Sankyo but now the subject of a $4 billion takeover by Indian rival Sun Pharmaceuticals.
European regulators also considered the corrective measures put in place by the company and were satisfied that the measures are sufficient to ensure GMP-compliant manufacture of products at the site. As a consequence, the EU authorities will reinstate the GMP certificate which was suspended in January 2014. The certificate will be re-entered into EudraGMDP, the EU database that contains GMP certificates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze